Abogen Biosciences

“Novartis will pay $575 million upfront for an mRNA-encoded T-cell engager that it believes could be applied to autoimmune diseases. The agreement also includes up to $7.2 billion in earnouts.”

“Abogen has raised over $1 billion from firms like SoftBank, 5Y Capital, Mirae Asset Management, Lilly Asia Ventures, Loyal Valley Capital, Hillhouse, PICC Capital, Qiming Ventures, and SDIC Venture Capital.”